Contraindicated in:
Use Cautiously in:
CV: orthostatic hypotension, MI.
Derm: melanoma, urticaria.
EENT: burning eyes, nasal stuffiness, visual disturbances.
GI: nausea, abdominal pain, anorexia, dry mouth, metallic taste, vomiting.
MS: leg cramps.
Neuro: dizziness, drowsiness, confusion, hallucinations, headache, impulse control disorders (gambling, sexual, uncontrolled spending, binge/compulsive eating), insomnia, nightmares.
Resp: effusions, pulmonary infiltrates.
Misc: digital vasospasm (acromegaly only).
Drug-Drug:
Parkinsonism
Hyperprolactinemia
Acromegaly
Pituitary Adenomas
Type 2 Diabetes (Cycloset only)
Therapeutic Classification: antiparkinson agents, antidiabetics
Pharmacologic Classification: dopamine agonists
Absorption: Parlodel is poorly absorbed (30%) from the GI tract; 6595% of Cycloset dose is absorbed (undergoes extensive first-pass metabolism; only 7% of dose reaches systemic circulation).
Distribution: 9096% protein bound.
Metabolism/Excretion: Completely metabolized by the liver (metabolized by CYP3A4); primarily excreted in bile (26% excreted unchanged in urine).
Half-life: Biphasicinitial phase 44.5 hr, terminal phase 820 hr.
(suppression of various parameters)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | 3090 min | 12 hr | 812 hr |
PO | 2 hr | 8 hr | 24 hr |
POi | 12 hr | 48 wk¶ | 48 hr |
PO | unknown | unknown | unknown |
Effect on parkinsonian symptoms.
Effect on serum prolactin levels.
iEffect on growth hormone.
¶During chronic therapy.
Effect on blood glucose levels.
NDC Code*